Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Buying $100 In NVO: If an investor had bought $100 of NVO stock 5 years ago, it would be worth $261.75 today based on a price ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy.

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product – insulin icodec – which backs up earlier data ...

Novo Nordisk has also embarked on a major capital investment programme to build manufacturing capacity in Europe and the US and is on course to spend around $6.8 billion this year, up from 3.9 ...

The “super pod” of Risso’s dolphins was spotted in Carmel Bay, off central California’s coast. This species, which can grow to over 10ft long and weigh as much as half a metric tonne ...

The fluoride controversy, where advocates and opponents argue in the media, is a distraction because the views of real and ...